首页> 外文期刊>Talanta: The International Journal of Pure and Applied Analytical Chemistry >Development and validation of a bioanalytical assay based on liquid chromatography-tandem mass spectrometry for measuring biomarkers of exposure of alternative plasticizers in human urine and serum
【24h】

Development and validation of a bioanalytical assay based on liquid chromatography-tandem mass spectrometry for measuring biomarkers of exposure of alternative plasticizers in human urine and serum

机译:基于液相色谱 - 串联质谱法的生物分析测定法测定人尿和血清替代增塑剂暴露生物标志物的生物分析测定

获取原文
获取原文并翻译 | 示例
       

摘要

Alternative plasticizers (APs) have been increasingly used in the last decade to replace conventional phthalate esters, in particular di(2-ethylhexyl) phthalate (DEHP), due to the toxicity of the latter. However, there is currently very little data about the toxicity of and exposure to APs. No method exists so far for the analysis of multiple exposure biomarkers. The objective of this work consisted in developing a simple bioanalytical procedure for the analysis of multiple exposure biomarkers of APs in human urine and serum. Focus was set on metabolites of di(2-propylheptyl) phthalate (DPrHpP), di(isononyl)cyclohexane-1,2-dicarboxylate (DINCH), di (2-ethylhexyl) terephthalate (DEHTP) and di-2-ethylhexyl adipate (DEHA). A sample preparation protocol was developed and optimized using Oasis HLB solid-phase extraction (SPE) cartridges. Subsequently, an instrumental method based on liquid-chromatography coupled to tandem mass spectrometry (LC-MS/MS) was optimized. Following established guidelines, the sample preparation and instrumental methods were validated in terms of recovery, matrix effects, carry-over, linearity, limits of quantification, within- and between-run precision and trueness. Obtained results were satisfactory for all compounds except for one of the metabolites of DEHA (i.e., mono(2-ethylhexyl) adipate (MEHA)). A pilot biomonitoring study was carried out to assess the method's ability to detect and quantify target analytes in human urine and serum. In urine, most analytes could be detected with frequencies ranging from 8% for mono(2-ethyl-5-hydroxyhexyl) adipate (OH-MEHA) and cyclohexane-1,2-dicarboxylic mono hydroxyisononyl ester (OH-MINCH) to 92% for mono(2-ethyl-5-oxohexyl) adipate (oxoMEHA), whilst most compounds could not be detected in serum, except for mono(2-ethylhexyl) terephthalate (MEHTP) and mono-(2-propyl-6-hydroxyheptyl) phthalate (OH-MPrHpP) which were detected in all samples. The obtained results show that the developed method can be used
机译:替代的增塑剂(APS)在过去的十年中越来越多地用于代替常规邻苯二甲酸酯,特别是由于后者的毒性,邻苯二甲酸酯(DEHP)。但是,目前有关APS的毒性和接触的毒性很少。到目前为止没有方法,用于分析多种曝光生物标志物。这项工作的目的是制定一种简单的生物分析程序,用于分析人类尿液和血清中APS的多次暴露生物标志物。将重点设置在Di(2-丙基庚基)邻苯二甲酸酯(DPRHPP),二(等壬基)环己烷-1,2-二羧酸甲酯(DICOCH),二(2-乙基己基)对苯二甲酸酯(DEHTP)和DI-2-乙基己基己二酸酯( Deha)。使用OASIS HLB固相提取(SPE)墨盒进行制备和优化样品制备方案。随后,优化了基于液相色谱法偶联的液相色谱法(LC-MS / MS)的仪器方法。在已建立的指导方针之后,在恢复,矩阵效应,随机,线性度,量化限制,在运行之间的恢复限制,以及运行之间的精度和自然之间进行验证。除了DEHA代谢物之外的所有化合物中获得的结果是令人满意的(即,单体(2-乙基己基)己二酸(Meha))。进行了试点生物监测研究,以评估方法检测和定量人尿液中靶分析物的能力。在尿液中,可以用频率从8%的频率检测到大多数分析物,用于单乙酸(2-乙基-5-羟基己基)和环己烷-1,2-二羧酸单羟羟基硅烷基酯(OH-MINCH)至92%对于己二酸盐(氧摩沙)的单乙醚(2-乙基-5-氧己基),而在血清中不能检测到大多数化合物,但除了单甲酸酯(2-乙基己基)对苯二甲酸酯(MEHTP)和单 - (2-丙基-6-羟基庚基)之外在所有样品中检测到邻苯二甲酸酯(OH-MPRHPP)。所获得的结果表明可以使用开发方法

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号